Wed Apr 4, 2007 7:28AM EDT
NEW YORK (Reuters Health) - The addition of exenatide (Byetta), the first in a new class of drugs called incretin mimetics, to a thiazolidinedione (TZD) in type 2 diabetes patients may improve control of blood sugar (glucose).
The addition of exenatide to thiazolidinediones (TZDs), drugs such as rosiglitazone or pioglitazone, that increase cell response to insulin, appears to results in better glucose control, researchers report in the Annals of Internal Medicine.
No comments:
Post a Comment